Immune-checkpoint inhibition for digestive cancers
Mené sur 65 patients atteints d'un carcinome épidermoïde de l'œsophage réfractaire, cet essai multicentrique de phase II évalue le taux de réponse objective et la toxicité du nivolumab
Oesophageal cancer, squamous-cell carcinoma, or adenocarcinoma, are frequently diagnosed at advanced stages and have poor prognosis. Despite decreasing incidence in squamous-cell carcinoma in many countries, the incidence of oesophageal cancer has not changed over time due to a rise in incidence of adenocarcinoma.1 Thus, oesophageal cancer remains the eighth most frequent cancer and the sixth most common cause of death from cancer worldwide.1
The Lancet Oncology , commentaire, 2016